• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to secondary sidebar

OINDPnews


Copley Scientific banner
  • Home
  • News
    • Business
    • Features
    • Medical
    • Regulatory
    • Products and Services
    • People
  • Events
  • Suppliers
    • Supplier listing and advertising options
    • Capsules and blisters
    • Consultants
    • Contract research
    • Contract manufacturing
    • Devices
    • Education
    • Excipients
      • Clinical Technology
    • Filling equipment
    • Instruments
    • Particle manufacturing
    • Software and modeling
  • Jobs
  • Resources
    • Webinars
    • White papers
  • LGWP Propellants
    • HFA 152a
    • HFO-1234ze(E)
    • LGWP Regulation
  • Contact

Pulmatrix licenses PUR0200 dry powder tiotropium to Vectura

Pulmatrix has announced a licensing agreement with Vectura for US development of Pulmatrix’s PUR0200 dry powder tiotropium formulation for the treatment of COPD. Vectura will pay Pulmatrix a $1 million “technology access fee” on achievement of certain milestones and will take responsibility for US development beginning immediately.

According its own announcement, Vectura will use PUR0200 to advance development of its VR410 branded tiotropium DPI, delivering the formulation using its own dry powder inhaler device technology, and then plans to license VR410 for final development and commercialization. Vectura may also choose to develop combination products that include PUR0200.

Mylan partnered with Pulmatrix on outside-of-US development of PUR0200 in 2015. In July 2016, Pulmatrix announced positive Phase 1 results for PUR0200 showing that the therapeutically equivalent dose for PUR0200 was significantly less than for Spiriva.

Pulmatrix CEO Robert Clarke commented, “Vectura has deep experience with inhaled drugs and innovative dry powder delivery technologies which makes them an optimal partner to advance PUR0200 as a better product for COPD patients. By out-licensing the program to Vectura, PUR0200 is in the hands of a partner with a demonstrated ability to develop drugs for COPD and allows Pulmatrix to focus on our product pipeline including PUR1900 and PUR1800.”

Vectura CEO James Ward-Lilley said, “With this agreement Vectura now has active substitutable or branded generic development programs for all the major established inhaled products in the US market. Tiotropium is one of the largest opportunities in the inhaled respiratory market and the agreement with Pulmatrix enables Vectura to accelerate its plans for both monotherapy and combination programs. The development of inhaled generics requires specialized capabilities which are scarce in the industry but are core competencies of Vectura. Today’s announcement is part of the expanded generic portfolio enabled through the merger of Vectura and Skyepharma.”

Read the Pulmatrix press release.

Read the Vectura press release.

Share

published on September 6, 2017

Primary Sidebar

Sign up for our free weekly newsletter

Upcoming Events
Sponsored by Intertek

Want information about upcoming OINDP-related events delivered directly to your inbox? click here

  • June 17-June 18: Rescon Europe 2025, Paris, France
  • June 19-June 20: Metered Dose Inhaler (MDI) Technology Training Course, online
  • June 22-June 25: ISAM Congress 2025, Washington, DC, USA
  • June 25-June 25: SMI.London 2025, London, UK
  • September 18-September 19: IPAC-RS Nasal Innovation Forum, West Trenton, NJ, USA
  • See all upcoming events

    Secondary Sidebar

    Suppliers

    Capsules and blisters
    Consultants
    Contract research
    Contract manufacturing
    Devices
    Education
    Excipients
    Filling equipment
    Instruments
    Particle manufacturing
    Software and modeling
    Catalent banner
    © 2025 OINDPnews